SKP1A Antibody

What is SKP1A and why is it important in cellular research?

SKP1A (S-phase kinase-associated protein 1A) functions as a critical assembly factor of the SKP1-CUL1-F-box protein (SCF) complex, also known as CUL1-RING ubiquitin ligases (CRL1s). This family of E3 ligases plays an essential role in the ubiquitin-proteasome pathway, marking specific proteins for degradation . Recent research has uncovered non-canonical functions of SKP1A beyond its E3 ligase activity, with particular importance in dopaminergic neuronal function and survival. SKP1A deficiency has been linked to increased vulnerability to neuronal damage in models of Parkinson's disease, highlighting its potential role in neurodegeneration . Additionally, SKP1A undergoes important post-translational modifications, including SUMOylation and phosphorylation at Thr131, which regulate its interactions and functions in various cellular processes .

What are the recommended applications and dilutions for SKP1A antibodies?

Based on validation data for SKP1A antibodies such as 10990-2-AP, the following applications and dilutions are recommended for optimal results:

For IHC applications, it's recommended to perform antigen retrieval with TE buffer pH 9.0 or alternatively with citrate buffer pH 6.0 . It's important to note that optimal dilutions may be sample-dependent, and researchers should conduct titration experiments to determine the best conditions for their specific experimental system. The antibody has shown reactivity with human, mouse, and rat samples, making it suitable for comparative studies across these species .

What tissues and cell types show significant SKP1A expression?

Neural tissues exhibit significant SKP1A expression, with particular importance in dopaminergic neurons. Research has demonstrated that SKP1A deficiency in substantia nigra-derived cell lines leads to increased vulnerability to parkinsonian toxins like MPP+ and to serum starvation . Various cancer cell lines, including HeLa (cervical cancer), MCF-7 (breast cancer), and HepG2 (liver cancer), have been used successfully for SKP1A detection . Additionally, validation data indicates expression in reproductive tissues such as mouse testis .

In experimental models, the embryonic mouse substantia nigra-derived cell line (SN4741) has been extensively utilized to study SKP1A function, demonstrating its importance in neuronal development and maintenance . When examining SKP1A expression patterns, researchers should employ multiple detection methods (protein and mRNA levels) to confirm expression profiles, as post-translational regulation may affect protein abundance independently of transcript levels.

How can researchers validate SKP1A antibody specificity in protein aggregation studies?

Validating SKP1A antibody specificity in protein aggregation studies requires a multi-faceted approach:

Genetic validation strategies: Implement gene silencing controls using shRNA or siRNA to knock down SKP1A expression. In SN4741 cells, approximately 70-80% reduction in mRNA was achieved with two different shRNA sequences, with corresponding reduction in protein signal by Western blot and immunofluorescence providing strong evidence of antibody specificity . Additionally, generate CRISPR-Cas9 knockout cell lines or use tissues from knockout animals when available. For positive controls, express tagged versions of SKP1A (e.g., Flag-tagged SKP1A) and confirm co-labeling with the SKP1A antibody.

Aggregation-specific validations: Compare antibody performance under normal versus aggregate-inducing conditions, such as differentiation conditions for SN4741 cells . Perform co-localization studies to confirm that SKP1A signal co-localizes with known aggregation markers (α-synuclein, ubiquitin, tyrosine hydroxylase, Hsc-70, proteasome subunits) in inclusion bodies . Quantitative analysis should be conducted—previous studies demonstrated that 42.7 ± 4.3% and 46.8 ± 5.1% of SKP1A-deficient cells showed inclusions co-staining for α-synuclein/TH and α-synuclein/ubiquitin, respectively .

Technical controls: Include secondary antibody-only controls to confirm absence of non-specific signal, use matched isotype antibodies to rule out non-specific binding, and optimize blocking reagents to minimize background staining. These comprehensive validation approaches ensure that observations regarding SKP1A in protein aggregation models reflect specific antibody recognition rather than artifacts or cross-reactivity.

What are the optimal protocols for co-immunoprecipitation experiments involving SKP1A?

Successful co-immunoprecipitation (Co-IP) of SKP1A and its interaction partners requires careful optimization of several key steps:

Buffer optimization: For standard Co-IP, use non-denaturing buffers (e.g., 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% NP-40 or Triton X-100, 5 mM EDTA) supplemented with complete protease inhibitor cocktail. When studying phosphorylation, include phosphatase inhibitors such as NaF (10 mM), Na₃VO₄ (1 mM), and β-glycerophosphate (10 mM). For SUMOylation studies, include N-ethylmaleimide (20 mM) to inhibit SUMO proteases .

Antibody selection and sample preparation: Use antibodies validated for IP applications, such as the 10990-2-AP SKP1A antibody which has been validated for Co-IP . Pre-clear samples by incubating lysate with protein A/G beads without antibody (1 hour at 4°C) and removing beads by centrifugation before proceeding to IP to reduce non-specific binding.

Special considerations for SKP1A interactions: For F-box protein interactions, use low stringency buffers as these interactions can be salt-sensitive. For SUMOylation-dependent interactions, perform IPs under conditions that preserve SUMOylation. Include appropriate controls such as SUMOylation-deficient (SKP1A RR) or phospho-mutants (T131A) . For SUMO-dependent interactions, include SIM mutants of interaction partners (e.g., PPM1B SIM-4A) .

Detection and quantification: For mass spectrometry-based identification of interaction partners, normalize peptide-spectrum match (PSM) counts based on the number of SKP1A peptides for accurate comparison. Previous research demonstrated that the PPM1B/SKP1A PSM ratio was 49% for SKP1A WT and only 2% for SKP1A RR , highlighting the importance of accurate normalization for quantitative comparison of interaction partners.

How do SKP1A phosphorylation states affect antibody recognition and experimental outcomes?

SKP1A phosphorylation states significantly impact antibody recognition and experimental outcomes through several mechanisms:

Phosphorylation at Thr131, a highly conserved site from yeast to humans, can alter protein conformation and epitope accessibility. If the epitope recognized by a standard SKP1A antibody includes or is near Thr131, phosphorylation could enhance or inhibit antibody binding, potentially leading to biased detection where one phosphorylation state is preferentially recognized. Phospho-specific antibodies such as pT131-SKP1 recognize only the phosphorylated form and must be validated using phospho-deficient mutants (T131A) and phospho-mimetic mutants (T131D, T131E) .

These variations in detection can substantially impact experimental outcomes. Western blot quantification may be skewed due to differential antibody affinity for phosphorylated versus non-phosphorylated forms. Immunoprecipitation efficiency may vary depending on phosphorylation state, and interpretation of subcellular localization in immunofluorescence studies may be affected if phosphorylation alters antibody recognition patterns.

The biological significance of SKP1A phosphorylation adds another layer of complexity. Research has shown that SKP1A phosphorylation at Thr131 is regulated by PPM1B phosphatase , and SUMOylation of SKP1A promotes its interaction with PPM1B, leading to dephosphorylation. The SUMOylation-deficient mutant (SKP1A RR) shows approximately threefold higher phosphorylation than wild-type SKP1A . These regulatory mechanisms likely affect SKP1A function in the SCF complex and should be considered when designing experiments.

How can SKP1A antibodies be employed to investigate neurodegeneration mechanisms?

SKP1A antibodies provide valuable tools for investigating neurodegeneration mechanisms through several sophisticated approaches:

Protein aggregation analysis: SKP1A deficiency has been linked to the formation of proteinaceous inclusions in neuronal models that share characteristics with Lewy bodies, containing α-synuclein, ubiquitin, tyrosine hydroxylase (TH), proteasome components, and Hsc-70 . Using SKP1A antibodies in co-labeling experiments with antibodies against these markers can characterize the composition of protein aggregates in neurodegeneration models. Immunohistochemistry with SKP1A antibodies on brain sections from neurodegenerative disease models or human post-mortem tissues can reveal changes in expression patterns. For optimal results in IHC applications, researchers should use antigen retrieval with TE buffer pH 9.0 or citrate buffer pH 6.0 as recommended for SKP1A antibodies .

Functional analysis of protective mechanisms: Research has demonstrated that enforced expression of wild-type SKP1A can protect against MPP+ toxicity and proteasomal inhibition in dopaminergic neuronal models . Using SKP1A antibodies to confirm overexpression and then assessing survival markers can provide insights into potential therapeutic strategies. Furthermore, examining changes in SKP1A SUMOylation or phosphorylation in disease models using modification-specific antibodies can reveal dysregulation of these regulatory mechanisms in neurodegeneration.

SCF complex functional analysis: Combining SKP1A antibodies with antibodies against F-box proteins and cullins in co-immunoprecipitation experiments can reveal alterations in complex formation in disease states, providing insights into how SKP1A deficiency affects its interaction with F-box proteins and other binding partners in the context of neurodegeneration .

What methodologies are recommended for studying SKP1A SUMOylation and its interactions?

Studying SKP1A SUMOylation and its interactions with phosphatases requires specialized techniques and careful experimental design:

SUMOylation detection protocols: Perform denaturing immunoprecipitation by lysing cells in conditions containing SDS and reducing agents, then diluting lysates to reduce SDS concentration before immunoprecipitation. Immunoprecipitate with SUMO-1 antibodies and perform Western blot with SKP1A antibodies to detect SUMOylated SKP1A . Research has shown that endogenous SKP1 is SUMOylated in human cells, with a preference for SUMO-1 over SUMO-2 or SUMO-3 .

Mutant analysis strategy: Generate SKP1A mutants where potential SUMOylation sites are mutated (e.g., SKP1A RR mutant) and express wild-type and mutant SKP1A in cells to compare SUMOylation levels by Western blot. These mutants serve as valuable controls in interaction studies. For SUMO-interaction motif (SIM) analysis, identify potential SIMs in interacting proteins (e.g., PPM1B) and generate SIM mutants (e.g., PPM1B SIM-4A with alanine substitutions) to test interaction with SUMOylated SKP1A by co-immunoprecipitation.

Mass spectrometry-based identification: Immunoprecipitate SKP1A wild-type and SUMOylation mutants and analyze copurified proteins by mass spectrometry. Compare peptide-spectrum matches (PSMs) to identify differential interactions . Previous research found 52 PSMs corresponding to the phosphatase PPM1B in the SKP1A WT IP compared to only 5 PPM1B PSMs in the SKP1A RR IP. Normalization based on the number of SKP1A peptides showed that the PPM1B/SKP1 PSM ratio was 49% for SKP1A WT and only 2% for SKP1A RR , highlighting the importance of appropriate normalization for accurate comparison.

When implementing these methods, researchers should be aware that SUMOylation often modifies only a small fraction of the total protein pool, making detection challenging. SUMO-overexpression systems can enhance signal but may not perfectly reflect physiological conditions.

How can SKP1A antibodies be used to study cell cycle regulation in neuronal models?

SKP1A antibodies offer powerful tools for studying cell cycle regulation in neuronal models through multiple experimental approaches:

Cell cycle phase analysis: Combine SKP1A antibody staining with cell cycle markers such as Ki-67 (proliferation), Cyclin D1 (G1 phase), Cyclin E (G1/S transition), PCNA (S phase), and Cyclin B1 (G2/M phase) to correlate SKP1A expression with specific cell cycle phases. Flow cytometric approaches can combine SKP1A staining with DNA content analysis for quantitative assessment of distribution across cell cycle phases.

Functional analysis in neuronal differentiation: Research has shown that SKP1A silencing significantly affects cell cycle progression in SN4741 cells, with decreased G0/G1 phase population (from 44.0% to 37.0-39.3%) and increased S phase population (from 25.3% to 29.1-32.7%), resulting in delayed completion of the cell cycle . Furthermore, SKP1A-deficient cells show impaired cell cycle arrest in G0/G1 when induced to differentiate . These phenotypes can be explored using SKP1A antibodies in combination with BrdU incorporation or EdU labeling to track S-phase entry.

Neurodegeneration model applications: Aberrant cell cycle re-entry is observed in neurodegenerative diseases, and SKP1A antibodies can help investigate whether altered SKP1A function contributes to this phenomenon. This is particularly relevant since SKP1A deficiency increases neuronal vulnerability to toxins like MPP+ and to serum deprivation . Pulse-chase experiments combining SKP1A antibody staining with BrdU/EdU labeling can track how SKP1A expression changes as cells exit the cell cycle or inappropriately re-enter it during neurodegeneration.

Implementing these approaches can provide insights into how SKP1A contributes to cell cycle regulation in neuronal models and how its dysregulation may contribute to neurodegenerative processes.

What fixation and antigen retrieval methods work best for SKP1A immunohistochemistry?

Different fixation and antigen retrieval methods significantly impact the detection of SKP1A in immunohistochemistry experiments:

Formalin-fixed paraffin-embedded (FFPE) tissue preparation: For clinical samples and many research applications using FFPE sections, effective antigen retrieval is essential. For SKP1A antibodies such as 10990-2-AP, it's specifically recommended to use TE buffer pH 9.0 as the primary retrieval solution, with citrate buffer pH 6.0 as an alternative option . Heating-based retrieval methods using pressure cooker, microwave, or water bath typically provide better results than enzymatic methods. These protocols have been validated successfully for human gliomas tissue and human lung cancer tissue .

Fresh frozen tissue and cell culture applications: For fresh frozen tissue sections, fixation with acetone or methanol (10-20 minutes at -20°C) typically preserves epitopes well but provides poorer morphology than FFPE methods. For cell cultures and some tissue sections, 4% paraformaldehyde (PFA) fixation typically provides a good compromise between antigen preservation and morphology, though permeabilization with Triton X-100 or saponin is usually necessary for antibody access to intracellular epitopes.

Technical considerations for optimal results: Regardless of the fixation method chosen, it's essential to block endogenous peroxidase activity when using HRP-conjugated secondary antibodies, especially in tissues with high peroxidase activity. Use appropriate blocking solutions (5-10% normal serum from the same species as the secondary antibody) to minimize background staining. Always include appropriate controls, including primary antibody omission controls and tissue/cell samples known to express or lack SKP1A to validate staining specificity.

The choice of fixation and antigen retrieval method should be guided by the specific research question, with consideration for preserving both the SKP1A epitope and any other antigens that may be co-detected in multiplex staining approaches.

What are the best practices for quantifying SKP1A levels in disease models?

Accurate quantification of SKP1A levels in neurodegenerative disease models requires rigorous methodological approaches:

Western blot optimization: Standardize protein extraction methods and normalize protein loading (20-50 μg total protein per lane) across all samples. Include positive controls such as HeLa or MCF-7 cells where SKP1A is well-expressed . Use RIPA or NP-40 buffers with protease/phosphatase inhibitors for extraction, and for SKP1A antibody 10990-2-AP, use a 1:500-1:1000 dilution for optimal results . Employ housekeeping proteins (β-actin, GAPDH) or total protein stains for normalization, and always include at least three biological replicates for statistical validity.

Immunohistochemistry/Immunofluorescence quantification: Use consistent fixation protocols and for FFPE sections, employ antigen retrieval with TE buffer pH 9.0 or citrate buffer pH 6.0 as recommended . For quantification, utilize digital image analysis software for unbiased assessment, measuring both signal intensity and area fraction. When analyzing brain tissue, different regions should be analyzed separately (e.g., substantia nigra, cortex) given the regional vulnerability patterns in many neurodegenerative diseases.

Post-translational modification analysis: Quantify phosphorylated SKP1A (pT131) using phospho-specific antibodies and assess SUMOylation levels using denaturing IP protocols . Compare modification ratios rather than absolute levels to account for variations in total protein. For subcellular distribution analysis, separate nuclear, cytoplasmic, and membrane fractions before quantification to identify compartment-specific changes in SKP1A levels or modifications.

Disease model-specific considerations: For Parkinson's disease models (toxin-based or genetic), measure SKP1A in relation to markers of neuronal loss and protein aggregation . For inclusion body analysis, quantify SKP1A-positive inclusions and measure co-localization coefficients with markers like α-synuclein, ubiquitin, and tyrosine hydroxylase . Statistical analysis should include appropriate tests based on data distribution, account for multiple comparisons when analyzing different brain regions, and report effect sizes in addition to p-values.

How can researchers overcome technical challenges when studying SKP1A isoforms?

Differentiating between SKP1A isoforms presents several technical challenges that can be overcome with strategic approaches:

Epitope accessibility optimization: SKP1A exists in different functional states (free versus complexed with F-box proteins), which can affect antibody accessibility. Antibodies raised against linear epitopes may not distinguish between functionally distinct forms, while conformational epitopes may be masked in certain protein complexes. To address this, use multiple antibodies targeting different epitopes and compare results across different extraction conditions that may preserve or disrupt specific complexes.

Post-translational modification differentiation: SKP1A undergoes SUMOylation and phosphorylation at Thr131 , with modified forms often representing only a small fraction of total SKP1A. To overcome detection challenges, employ enrichment strategies such as SUMOylation-enrichment protocols or phospho-enrichment methods (IMAC or phospho-antibody enrichment) prior to analysis. Generation of isoform-specific antibodies against unique regions or splice junctions, and use of modification-specific antibodies such as phospho-specific pT131-SKP1 antibodies can significantly improve discrimination between different forms.

Enhanced separation techniques: Standard Western blot resolution may be insufficient to separate closely sized isoforms. Employ 2D gel electrophoresis before Western blotting to separate isoforms based on both size and charge. Alternatively, use immunoprecipitation followed by mass spectrometry to identify specific isoforms with greater precision than antibody-based methods alone.

Rigorous validation approaches: Test antibodies on samples with known SKP1A variants and use genetic models (knockout, knockdown, overexpression) to validate specificity. Include SKP1A mutants (e.g., T131A, T131D, T131E) as controls for phospho-specific antibodies . For cross-reactivity concerns, validate against related family members using specific knockdown approaches for each potential cross-reacting protein.

These strategies can help researchers overcome the technical limitations and achieve more precise identification of specific SKP1A isoforms in their experimental systems.